Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term vonoprazan safety vs lansoprazole in erosive esophagitis
jRCTs031180040Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of vonoprazan in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (2 arms), sponsored by Takeda. Primary endpoint: Percentage of participants with clinically significant gastric mucosa histopathology findings. Started Apr 2016; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on jRCTs031180040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180040.